Antigripping Vaccine Recipients
- Sanofi's Efluelda vaccine, specifically formulated to enhance flu protection for individuals over 65, is set to return to France's vaccination program.
- This policy shift follows a especially severe 2024-2025 flu season, prompting health authorities to reassess strategies for safeguarding vulnerable populations.
- as individuals age, their immune systems naturally weaken, leading to a diminished response to standard vaccines.
Sanofi’s Efluelda Vaccine Returns to France for 2025-2026 Flu Season
Table of Contents
- Sanofi’s Efluelda Vaccine Returns to France for 2025-2026 Flu Season
- Efluelda Vaccine: Your Questions Answered for the 2025-2026 Flu Season in France
Sanofi’s Efluelda vaccine, specifically formulated to enhance flu protection for individuals over 65, is set to return to France’s vaccination program. After a year’s absence due to a pricing disagreement, the vaccine now has the backing of the High Authority for Health (HAS), which recommends it as the preferred option for seniors.
This policy shift follows a especially severe 2024-2025 flu season, prompting health authorities to reassess strategies for safeguarding vulnerable populations. Efluelda received market authorization in November 2024,with a distribution campaign planned for October 2025.
High-Dose Vaccine Tailored for Seniors
as individuals age, their immune systems naturally weaken, leading to a diminished response to standard vaccines. Efluelda addresses this issue with a formulation containing four times more antigens than conventional vaccines. This increased dosage aims to stimulate a more robust immune response in older adults.
The Driven study, conducted in France, demonstrated that Efluelda reduced flu-related hospitalizations by 23.3% in individuals over 65 compared to standard vaccines. Thes findings support the decision by health authorities to reinstate efluelda as a key component of the national prevention strategy.
Efluelda offers enhanced protection tailored to the specific needs of the most vulnerable population.
Trivalent Formula Aligned with Global Recommendations
Efluelda will be available in a trivalent formulation. This adjustment reflects the disappearance of the B/Yamagata strain from circulation, rendering quadrivalent vaccines unnecessarily broad. The World Health Association (WHO) and the European Medicines Agency (EMA) have revised their recommendations accordingly, and Sanofi has adapted its formula.
This refined approach ensures targeted protection against the most prevalent strains, maintaining the vaccine’s effectiveness against current epidemic risks.
Logistical Preparations for Effective Distribution
To avoid past shortages, Sanofi is working with pharmacists and health professionals to streamline distribution. Pre-orders have commenced, and facts is being disseminated to ensure vaccine availability at the campaign’s launch in October 2025.
Health professionals are encouraged to anticipate demand, as strong support from scientific and institutional bodies is expected to drive high demand.
A Critical Public Health Imperative
According to Public Health France, seasonal influenza causes between 8,000 and 14,000 deaths annually in France, primarily among individuals over 65. By providing a stronger immune response, Efluelda targets the severe forms of the illness that often lead to hospitalization or death.
The return of Efluelda represents a strategic public health initiative aimed at caregivers, families, and patients.
NOTE:
The High Authority for Health advises that Efluelda can be administered concurrently with a COVID-19 vaccine at separate injection sites.
Efluelda Vaccine: Your Questions Answered for the 2025-2026 Flu Season in France
What is Efluelda and Why Is It Critically important?
What is Efluelda?
Efluelda is a flu vaccine specifically designed to provide enhanced protection for individuals over the age of 65. It is manufactured by Sanofi and is set to return to the French vaccination program for the 2025-2026 flu season.
Why is Efluelda being reintroduced?
Efluelda is being reintroduced after a year’s absence due to a pricing disagreement. The High Authority for Health (HAS) now recommends it as the preferred option for seniors, following a particularly severe 2024-2025 flu season. The reintroduction aims to safeguard vulnerable populations, especially the elderly.
What Makes Efluelda Different?
How dose Efluelda work?
Efluelda uses a high-dose formulation, containing four times more antigens than standard flu vaccines, to stimulate a more robust immune response in older adults. This is particularly critically important as,as we age,our immune systems naturally weaken,leading to a diminished response to standard vaccines.
How effective is Efluelda in protecting seniors?
A study conducted in France, known as the Driven study, demonstrated Efluelda’s efficacy. It showed that Efluelda reduced flu-related hospitalizations by 23.3% in individuals over 65 compared to standard vaccines, supporting its reintroduction and the HAS’s suggestion.
Key Features of the Efluelda Vaccine
What is the formulation of efluelda for the 2025-2026 flu season?
Efluelda will be available in a trivalent formulation. This means it is designed to protect against three strains of the flu.
Why a trivalent formula?
The trivalent formula is due to the disappearance of the B/Yamagata strain from circulation. The World health Organization (WHO) and the European Medicines Agency (EMA) have adjusted their recommendations accordingly, and Sanofi has adapted its formula to ensure targeted protection against the most prevalent strains.
Availability and Distribution
When will the Efluelda vaccine be available in France?
The distribution campaign for Efluelda is planned for October 2025.
How is Sanofi preparing for distribution?
To avoid past shortages,sanofi is working with pharmacists and health professionals to streamline distribution. Pre-orders have already commenced,and details is being disseminated to ensure vaccine availability at the campaign’s launch,which would be by October 2025.
Public Health Importance
Why is flu vaccination crucial for seniors?
Seasonal influenza causes between 8,000 and 14,000 deaths annually in France, primarily among individuals over 65. Efluelda’s stronger immune response targets the severe forms of the illness that often lead to hospitalization or death, making vaccination a critical public health initiative.
Who can receive Efluelda?
Efluelda is specifically designed for individuals over 65, a population most vulnerable to severe complications from the flu.
Additional Information
Can I get the Efluelda vaccine and a COVID-19 vaccine simultaneously occurring?
Yes. The High Authority for Health advises that Efluelda can be administered concurrently with a COVID-19 vaccine, but at separate injection sites.
Key Takeaways
Here is a summary of the key aspects of the Efluelda vaccine:
| Feature | Details |
|---|---|
| Target population | Individuals over 65 |
| Formulation | Trivalent (protects against three strains) |
| Mechanism | High-dose formulation (four times more antigens than standard vaccines) |
| Effectiveness | reduced flu-related hospitalizations by 23.3% in those over 65 (Driven study) |
| Availability | Campaign launch planned for october 2025 |
| Co-management | Can be administered concurrently with a COVID-19 vaccine at separate injection sites |